Pharma Sector Check - Covid-19 Vaccine Opportunity - Will It Sustain? Nirmal Bang Insight
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
There is a debate underway on the use of booster doses for Covid-19, but broadly, most regulators so far have remained unconvinced.
The World Health Organisation continues to remain non-committal when it comes to recommending the use of booster doses in general population.
WHO is currently evaluating data, but believes that evidence remains limited and inconclusive on any widespread need for booster doses following a primary vaccination series.
U.S. Food and Drug Administration’s advisory committee has also recently voted against the use of booster doses of Pfizer and Moderna vaccines in general population.
However, it has recommended the use of booster doses for the immunocompromised population and elderly (more than 65 years of age).
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.